Fundraising Fox

Ambagon Therapeutics

Eindhoven, US · Founded 2020 · Delaware corporation · 7 known investors

ambagontx.com ↗

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical Devicesin /ambagon-therapeutics@ambagontx

Founders & leadership

CO
Christian OttmannExecutive Officer
JS
Josh SeidenfeldExecutive Officer
MA
Michelle ArkinDirector
NP
Nancy PryerExecutive Officer
MC
Margarita ChavezDirector
PD
Peter DudekDirector
JN
Janwillem NaesensDirector
BM
Bryan MillerExecutive Officer
RB
Roel BulthuisDirector
AR
Adam RosenbergDirector
SC
Scott ClarkeExecutive Officer, Director
MM
Melissa McCrackenDirector

Investors · 7

Droia VenturesLeuven · $540Kvia Janwillem Naesens · board
Mission BiocapitalSan Francisco · $500K
MRL Ventures FundCambridge · $25M
Nextech InvestZurich · $648K – $3.2M
InkefreportedAmsterdam
RA CapitalreportedBoston
SynconareportedLondonvia Roel Bulthuis · board

Reported raises · per SEC filings

Form D private placements
▶$5MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Melissa McCrackenDirector
  • Josh SeidenfeldExecutive Officer
  • Christian OttmannExecutive Officer
Offering amount
$12M
Amount sold
$5M
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$45MraisedJun 2022 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Josh SeidenfeldExecutive Officer
  • Michelle ArkinDirector
  • Peter DudekDirector
  • Roel BulthuisDirector
  • Janwillem NaesensDirector
  • Margarita ChavezDirector
  • Nancy PryerExecutive Officer
  • Christian OttmannExecutive Officer
  • Adam RosenbergDirector
  • Melissa McCrackenDirector
  • Bryan MillerExecutive Officer
  • Scott ClarkeExecutive Officer, Director
Offering amount
$85M
Amount sold
$45M
First sale
Jan 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.4MraisedDec 2021 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michelle ArkinDirector
  • Nancy PryerExecutive Officer
  • Christian OttmannExecutive Officer
  • Margarita ChavezDirector
  • Peter DudekDirector
  • Janwillem NaesensDirector
  • Bryan MillerExecutive Officer
  • Roel BulthuisDirector
  • Adam RosenbergDirector
  • Josh SeidenfeldExecutive Officer
  • Scott ClarkeExecutive Officer, Director
Offering amount
$5.4M
Amount sold
$5.4M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news